The Interferon Papers
The good news just keeps on coming. Now, in addition to breakthrough research presented at ASH 2012 we have three of the foremost MPN specialists in the world collaborating on a comprehensive overview of the one medicine proven to produce hematological remission and reverse fibrosis in MPN!
“Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis” is the paper produced by Richard T. Silver, Jean-Jacques Kiladjian and Hans Carl Hasselbalch, just published by Expert Reviews-Hematology.
Far more than a retrospective study, this paper sets out highly specific therapeutic targets in each MPN phenotype and includes dosage recommendations so critical to avoid side effects and achieve maximum benefit. Hard to believe this won’t become the go-to document for healthcare providers, patients and caregivers.
MPNforum Magazine has scheduled “The Interferon Papers,” a detailed review of the paper and associated documents, case studies and interviews for our March issue.
- The two newest participants in the MPNclinic , Dr. Hans Carl Hasselbalch and Dr. Jean-Jacques Kiladjian have joined the senior MPNclinic member, Dr. Richard T. Silver on the panel Questions to MPNclinic can be sent to firstname.lastname@example.org
Comments on: "Coming up: The final word on interferon" (7)
Looking forward to reviewing the full Interferon Papers.
Very exciting stuff, Zhen!
The addition of Dr. Hans Hasselbalch to our MPNclinic, sitting alongside Dr. Richard Silver, gives us two of the most deeply experienced and innovative world-class views of the interferons…as you’ll see from the February 15 MPNclinic. They should be joined by another decisive voice in hematology, Dr. Jean-Jacques Kiladjian, the third author of that seminal paper, in March. All in all, I suspect we will know the full promise and limits of the interferons before it’s all over. The interferons exist in a therapeutic context that includes several other therapies, combined or in isolation, and if you look over the MPNclinic roster you’ll recognize the balancing presence of Principal Investigators in alternatives drugs. We’re honored…and we’re blessed by their presence. (And a little lucky, too.)
Zhen, you never cease to amaze me with your well researched reviews, clinical interpretations (sometimes simplified) and new resources introduced to the MPN world. I am still hampered by sometimes crushing fatigue among other things (I did answer the survey), but remain optimistic!
I was on Interferon for about 10 years and it kept my blood counts near to “normal”. I had no side effects after the first fortnight and was on 6mu 3xweek. It kept my spleen under control and I had no more itching and did not suffer from fatigue and I worked full time without any problems. I was diagnosed with PV in 1994 and unfortunately my hem/onc at the time did not believe in Interferon and then in 2000 I was diagnosed with MF and I then changed doctors and he agreed I could try Interferon but warned me about the side effects. They lasted for the fortnight and then I never looked back until once more my spleen started to grow back and I then went on a clinical trial CYT387 and after 4 months I found my spleen was even larger, my skin became mottled and I stopped the drug and am now on Jakafi and have been for 6 months and my spleen has once more retracted. I feel if I had been taking Interferon when I had PV I may not have developed MF.
Very much looking forward to reading the Interferon Papers as I am planning to go on Pegasys soon.